Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00179127 · ClinicalTrials.gov registry record · NA
Use of Insulin Glargine to Treat Diabetic Ketoacidosis
A NA study of Diabetic Ketoacidosis, sponsored by Vanderbilt University Medical Center.
- Completed
- Registry status
- NA
- Development phase
- 75
- Enrollment target
- 1
- Study location
NCT00179127 is a NA study of Diabetic Ketoacidosis that has completed, run by Vanderbilt University Medical Center. The registered enrollment target is 75 participants, above the 38-participant average among 3 other Diabetic Ketoacidosis trials with a reported enrollment target (97% higher). The trial reports 1 study location across 1 state.
The verdict
NCT00179127, a NA study of Diabetic Ketoacidosis, has completed, sponsored by Vanderbilt University Medical Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 75 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine the effects of the addition of insulin glargine during the early phase of moderate to severe Diabetic Ketoacidosis (DKA) in children. The investigators hypothesize that the addition of insulin glargine during the early phase of management of DKA will accelerate acidosis correction, decrease the length of insulin infusion, and decrease the total intensive care unit time in children admitted to the ICU.
Conditions Studied
Interventions
- DRUG saline
- DRUG glargine
Study Locations (1)
Tennessee
- Vanderbilt University Monroe Carell Children's Hospital - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2004-08 |
| Est. Completion | 2012-09 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00179127
The ClinicalTrials.gov registry entry for NCT00179127 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 38-participant average among 3 other Diabetic Ketoacidosis trials with a reported enrollment target (97% higher). The listed sponsor is Vanderbilt University Medical Center, which has 677 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Diabetic Ketoacidosis appearing as the primary indexed condition, and to 2 interventions - of which saline is the first listed.
NCT00179127 reports 1 study location spanning 1 distinct geographic area - top geographies include Tennessee.
Frequently Asked Questions
What is clinical trial NCT00179127 about?
NCT00179127 is a clinical study titled "Use of Insulin Glargine to Treat Diabetic Ketoacidosis". The purpose of this study is to determine the effects of the addition of insulin glargine during the early phase of moderate to severe Diabetic Ketoacidosis (DKA) in children. The investigators hypothesize that the addition of insulin glargine during the early phase of management of DKA will accele...
What is the current status of trial NCT00179127?
This trial is currently completed. It is a NA study. The enrollment target is 75 participants. The study started on 2004-08. Estimated completion is 2012-09.
What conditions does trial NCT00179127 study?
This clinical trial studies the following conditions: Diabetic Ketoacidosis.
What interventions are being tested in trial NCT00179127?
The interventions under investigation include: saline (DRUG), glargine (DRUG).
Who is sponsoring clinical trial NCT00179127?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00179127 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetic Ketoacidosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.